Protagonist Therapeutics, Inc.
🏢 View company profile →32Patents
32Active
32Granted
53Portfolio score
Filing activity: Oct 10, 2013 → Sep 28, 2023
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9273093B2 | α4β7 peptide dimer antagonists | Human Necessities | 29 | Active |
| US9518091B2 | A4B7 peptide monomer and dimer antagonists | Human Necessities | 28 | Active |
| US9624268B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | Physics | 26 | Active |
| US9822157B2 | Hepcidin analogues and uses thereof | Human Necessities | 25 | Active |
| US9809623B2 | α4β7 peptide monomer and dimer antagonists | Human Necessities | 24 | Active |
| US9714270B2 | a4B7 integrin thioether peptide antagonists | Human Necessities | 24 | Active |
| US10030061B2 | Hepcidin analogues and uses thereof | Human Necessities | 21 | Active |
| US10035824B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | Physics | 19 | Active |
| US10059744B2 | α4β7 thioether peptide dimer antagonists | Human Necessities | 19 | Active |
| US10023614B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | Physics | 19 | Active |
| US10196424B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | Physics | 17 | Active |
| US10301371B2 | Cyclic monomer and dimer peptides having integrin antagonist activity | Human Necessities | 16 | Active |
| US10442846B2 | Hepcidin analogues and uses thereof | Human Necessities | 15 | Active |
| US10501515B2 | Hepcidin analogues and uses thereof | Human Necessities | 15 | Active |
| US10278957B2 | Opioid agonist peptides and uses thereof | Chemistry; Metallurgy | 13 | Active |
| US10787490B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | Human Necessities | 13 | Active |
| US10626146B2 | α4β7 thioether peptide dimer antagonists | Human Necessities | 12 | Active |
| US10407468B2 | Methods for synthesizing α4β7 peptide antagonists | Human Necessities | 11 | Active |
| US11041000B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | Chemistry; Metallurgy | 8 | Active |
| US11111272B2 | α4α7 peptide monomer and dimer antagonists | Human Necessities | 8 | Active |
| US10941183B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | Physics | 8 | Active |
| US10729676B2 | Opioid agonist peptides and uses thereof | Chemistry; Metallurgy | 8 | Active |
| US11472842B2 | Analogues of hepcidin mimetics with improved in vivo half lives | Human Necessities | 4 | Active |
| US11753443B2 | Conjugated hepcidin mimetics | Human Necessities | 2 | Active |
| US11807674B2 | Hepcidin analogues and uses thereof | Human Necessities | 2 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.